Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevurogant
- Development stage
- Phase 2
- Lead developer
- Boehringer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Bevurogant (BI 730357)** is a small molecule **RORγt inhibitor** (also known as RAR-related orphan receptor gamma 2 inhibitor) developed by **Boehringer Ingelheim** for autoimmune and inflammatory diseases. It acts as an antagonist to RORγt, a nuclear receptor that regulates Th17 cell differentiation and IL-17 production, key drivers of pathologies like psoriasis. The drug reached **Phase 2** trials for plaque psoriasis, psoriatic arthritis, and chronic large plaque psoriasis but appears stalled or discontinued, with no recent updates from the developer.[1][3][5][13]
- Other names
- Percoffedrinol-Boehringer Ingelheim-plaque psoriasis
02
Targets
RORγt
Beyond the preview
Go deeper on bevurogant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevurogant.